Logo image
LBP-025 Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebocontrolled, phase 2 trial
Journal article   Peer reviewed

LBP-025 Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebocontrolled, phase 2 trial

Rohit Loomba, Kris Kowdley, Muhammad Y. Sheikh, Nomita Kim, Anita Kohli, Eric Lawitz, Brenda Jeglinski, Kelly Kutch, Jose Manuel Trigo, Patricia Mendez, …
Journal of hepatology, Vol.84, pp.S78-S79
05/2026

Metrics

1 Record Views

Details

Logo image